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Malignant hypertension develops in some cases of hypertension but not in others.
We hypothesized that an impaired neovascularization and a reduced capillary supply
characterizes the malignant course of experimental hypertension. Two-kidney, one-clip
renovascular hypertension was induced in rats; controls (sham) were sham operated.
To distinguish malignant hypertension from non-malignant hypertension, we considered
two factors: weight loss, and the number of typical vascular lesions (onion skin
lesions and fibrinoid necroses) per kidney section of the nonclipped kidney. Animals
in the upper half for both criteria were defined as malignant hypertensives. After 5
weeks, mean arterial blood pressure was elevated to the same degree in malignant
hypertension and non-malignant hypertension whereas plasma renin and aldosterone
were significantly higher in malignant hypertensives. The expression of plasminogen
activator inhibitor-1 was elevated (up to 14-fold) in non-malignant but significantly more
increased (up to 36-fold) in malignant hypertensive rats, compared to sham. As a
bioassay for neovascularization, the area of granulation tissue ingrowth in polyvinyl
discs (implanted subcutaneously) was reduced in malignant hypertension compared
to non-malignant hypertension and sham, while there was no difference between
non-malignant hypertension and sham. The number of renal and left ventricular
capillaries was significantly lower in malignant hypertension compared to non-malignant
hypertension, as was the number of proliferating endothelial cells. We conclude that
an impaired neovascularization and capillarization occurs in malignant renovascular
hypertension but not in the non-malignant course of the disease despite comparable
blood pressure levels. This might contribute to the unique vascular lesions and
progressive target organ damage observed in malignant hypertension.
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INTRODUCTION
Malignant hypertension is a serious complication of high blood
pressure characterized by progressive target organ damage (Lip
et al., 1995; Shantsila et al., 2010). Characteristic morphological
lesions of the smaller blood vessels with proliferative onion skin
lesions in the renal vasculature, and thrombotic microangiopathy
are typical features of this condition. Presumably due to
the availability of a variety of antihypertensive drugs, the
prognosis of malignant hypertension has improved considerably
in recent decades (Gonzalez et al., 2010). Nevertheless, successful
treatment of this condition remains a challenge (Shantsila et al.,
2010), and some patients continue to suffer from progressive
target organ damage (Gonzalez et al., 2010). Further, it remains
unclear why some patients developmalignant hypertension while
others do not. Data from animal models of hypertension point
to a role for the renin-angiotensin-aldosterone system in the
development of malignant hypertension (Möhring et al., 1976;
Luft et al., 1999; Hartner et al., 2006). Chronic activation of the
renin-angiotensin system as seen in these models is associated
with activation of inflammatory mechanisms, like overexpression
of chemokines, macrophage infiltration, or activation of the
complement system (Hilgers et al., 2001; Shagdarsuren et al.,
2005). These changes, however, can also occur in non-malignant
hypertension.
Endothelial dysfunction was shown to occur in malignant
hypertension (Shantsila et al., 2011). Blockade of endothelin
receptors prevented the development of malignant hypertension
in some models of hypertension (Li et al., 1996; Orth et al., 1998),
but was only partially effective in other models (Muller et al.,
2000) and had even no effect at all in one model (Whitworth
et al., 1995; Orth et al., 1998). Another possible endothelial
pathomechanism is a disruption of endothelial regeneration. In
some forms of thrombotic microangiopathy (e.g., preeclampsia
or sirolimus-induced thrombotic microangiopathy), which share
several morphological features with malignant hypertension,
the expression or function of endothelial growth factors, like
vascular endothelial growth factor (VEGF), is impaired (Levine
et al., 2004; Sartelet et al., 2005). Inhibition of angiogenesis
with anti-VEGF antibodies or inhibition of the VEGF receptor
in cancer patients can induce hypertension or lead to an
increase in preexisting hypertension (Sandler et al., 2004;
Holden et al., 2005). There are even reports describing the
development of malignant hypertension in patients treated
with VEGF inhibitors (Caro et al., 2013). Moreover, an
inhibition of VEGF receptor enhanced blood pressure in a
rat model of salt-induced hypertension (Gu et al., 2009)
and caused hypertension in mice (Facemire et al., 2009).
Additionally, anti-angiogenic treatment in a transgenic rat model
of hypertension caused glomerular damage in the kidneys
with transformation to a malignant hypertensive phenotype
(Advani et al., 2007). The similarity of the effects of anti-
angiogenic therapy on the one hand, and spontaneous malignant
hypertension on the other hand, prompted us to investigate
the possibility that an impairment of angiogenic mechanisms
may underlie the spontaneous development of malignant
hypertension.
In our study we therefore used a rat model of malignant
hypertension to compare the regenerative capacity of the
vasculature in animals with malignant vs. non-malignant
hypertension. We hypothesized that animals with malignant
hypertension would exhibit a decreased neovascularization
(measured by the disc angiogenesis bioassay) and a markedly
impaired capillary supply of the kidney and heart compared to
animals with non-malignant hypertension.
MATERIALS AND METHODS
Renovascular Hypertension
Rats were housed in a roommaintained at 22± 2◦C, exposed to a
12 h dark/light cycle. The animals were allowed unlimited access
to chow (#1320, Altromin, Lage, Germany) and tap water. All
procedures performed on animals were done in compliance with
the DIRECTIVE 2010/63/EU of the European Parliament and
were approved by the local government authorities (Regierung
of Mittelfranken, AZ 54-2532.1-51/12). Two-kidney, one-clip
renovascular hypertension (2K1C) was induced in male Sprague-
Dawley rats (Charles River, Sulzfeld, Germany) weighing 150–
170 g by placing a silver clip of 0.2mm internal diameter
around the left renal artery through a flank incision under
isoflurane anesthesia (using a vaporizer; starting with 5%, then
followed by 1.5–2% via face mask) as previously described (Mai
et al., 1995) (n = 59). Control animals underwent sham
operation without placement of the clip (n = 25). Analgesia
with subcutaneous buprenorphine injections (0.05mg/kg) was
provided post-operatively in all animals, and as needed later on.
Weight and systolic blood pressure (tail cuff plethysmography)
were measured weekly. During 5 weeks of follow-up, 12 2K1C
rats died or had to be euthanized after severe weight loss
and seizures and/or hemiplegia; these rats were not included
in the analysis. Five weeks after clipping of the renal artery,
the experiment was terminated and renal tissue was studied
for the presence of onion skin lesions and fibrinoid necroses
(assessed by two different blinded observers in two non-serial
kidney sections) in all contralateral kidneys exposed to high
blood pressure (Möhring et al., 1976; Hilgers et al., 2001). The
criteria used for the definition of malignant hypertension in this
study (see Section Results) were adapted from long-standing
observations of weight loss and characteristic vascular lesions
(Möhring et al., 1976; Hilgers et al., 2001) as hallmarks of the
disease.
Disc Angiogenesis Assay
After mounting of nitrocellulose filters on the polyvinyl alcohol
sponges (Rippey, El Dorado Hills, CA, USA), the discs were
autoclaved and implanted subcutaneously for 3 weeks as
described elsewhere (Fajardo et al., 1988; Jacobi et al., 2005).
Two discs per rat were implanted 2 weeks after clipping.
Vascularization of the discs was assessed as described by Fajardo
et al. (1988) by measuring the ingrowth of fibrovascular tissue
(granulation tissue) which mirrors the ingrowth of vessels, as
delineated in a more extensive method description published
by Kowalski et al. (1992) and Jang et al. (2000). Fibrovascular
tissue ingrowth was evaluated by two methods: photographs
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TABLE 1 | Primer pairs.
Forward Reverse
VEGF-A 5′- AAC GAA AGC GCA AGA AAT CC -3′ 5′- GCT CAC AGT GAA CGC TCC AG -3′
VEGF-B 5′- TGT ACC CAG GCC CCT GTG T -3′ 5′- GCA CGT GCA TAA ACA TCT ATC CA -3′
VEGF-C 5′- CAG CAA GAC GTT GTT TGA AAT TAC A -3′ 5′- GTG ATT GGC AAA ACT GAT TGT GA -3′
VEGF-D 5′- ACA CCG AGC AGT GAA GGA TG -3′ 5′- AAC ACA GAC CGG GAT GAT CG -3′
VEGF-R1 5′- CGA CAC TCT TTT GGC TCC TTC TAA C -3′ 5′- TGA CAG GTA GTC CGT CTT TAC TTC G -3′
VEGF-R2 5′- CCA CCC CAG AAA TGT ACC AAA C -3′ 5′- AAA ACG CGG GTC TCT GGT T -3′
VEGF-R3 5′- CAT TGT GCA CGA AAA GCC CT -3′ 5′- CGG GTA GCT TCA CCA TCT CG -3′
PlGF 5′- TAT GGA GCA CCA CTG ATG GA -3′ 5′- TCA GCC AGG CTT TGA GAT TT -3′
PAI-1 5′- GTT CAC CAC TCC GGA TGG G -3′ 5′- TGG TAG GGC AGT TCC AGG AT -3′
AP-1 5′- AAA CCA CAC GGC CAC CAT -3′ 5′- TGG ATT TCA AGA CGG GAT GT -3′
probe: TGG AGA TAG GAA CCA GCC TCT TGT CTC AGA CT
AP-2 5′-GAC CAG TGG GCA TCG CTA CG -3′ 5′- CAT TGT CCG AAT CCT TTG TGC T -3′
probe: AAG GCA GCG AGG CAC ACT CTC TGT ATG AG
Tie1 5′-GCC CCA GGA CAG CAT GAT TA-3′ 5′- TCT CAC TGG GAT CCA CCA CA -3′
Tie2 5′-GCT GGA AGA ACG AAA GAC ATA CG -3′ 5′- GCT CTC GTG CCA GTG AAG AGA -3′
18S 5′- TTG ATT AAG TCC CTG CCC TTT GT -3′ 5′- CGA TCC GAG GGC CTC ACT A -3′
List of primers pairs and probes used in the study.
FIGURE 1 | Photomicrographs of PAS stained renal sections
representative for 25 control animals, 15 non-malignant hypertensive
animals, and 13 animals with malignant hypertension. (A) Renal section
from a sham OP control; (B) Renal section from an animal with non-malignant
hypertension. Arrows mark renal artery. (C,D) Renal sections from animals with
malignant hypertension (C, arrows mark fibrinoid necroses. D, arrows mark
onion skin lesion).
of the polyvinyl discs immediately after explantation and
removal of the nitrocellulose filters were scanned for later
quantification (see Figures 4A–C); and quantification of the
tissue area observed in PAS-stained sections (after fixation of
the disc with 3% paraformaldehyde, embedding in paraffin and
cutting 2µm sections) under the microscope in low-power
views. The vascularized area was evaluated as percentage of
the entire disc area. There was a good correlation between
both methods (correlation coefficient [Spearman’s rho]: 0.792);
the data shown below are the results from the direct visual
examination. The disc angiogenesis method was selected because
it is a dynamic assay, because its development over time matches
well with the length of the time period during which malignant
hypertension is expected to occur, and because it is a rather small
additional burden for the animals (compared to e.g., hindlimb
ischemia).
Blood Pressure Measurements
Systolic blood pressure was measured weekly by tail cuff
plethysmography using a modification of previously described
techniques (Williams et al., 1939) under light isoflurane
anesthesia (starting with 2% for induction, followed by 0.5% via a
face mask). At the end of the experiment rats were instrumented
with femoral artery catheters for intraarterial blood pressure
measurements as described previously (Menendez-Castro et al.,
2011). Measurements were performed on the same day after
termination of anesthesia and a recovery phase of 2 h in conscious
animals via transducers connected to a polygraph (Hellige,
Freiburg, Germany).
Measurement of Plasma Creatinine,
Aldosterone, Renin Activity, VEGF, and
Soluble VEGF Receptor
Blood for analysis was collected from indwelling catheters.
Thereafter, rats were killed by bleeding in deep anesthesia.
Plasma creatinine was analyzed using an automatic analyser
Integra 800 (Roche Diagnostics, Mannheim, Germany). Plasma
aldosterone was measured with a commercially available
Frontiers in Physiology | www.frontiersin.org 3 August 2016 | Volume 7 | Article 370
Hartner et al. Capillary Supply and Neovascularization in Hypertension
TABLE 2 | Body and organ weights, physiologic parameters and markers of organ damage.
Sham-OP control Non-malignant hypertension Malignant hypertension
Body weight at OP (g) 151.2±1.4 151.7± 1.8 151.8±2.4
Body weight at sacrifice (g) 381.0±8.0 343.6± 9.4* 251.4±7.5*,†
Kidney weight (right, unclipped) (g) 1.22±0.02 1.44± 0.06* 1.40±0.10*
Kidney weight (left, clipped) (g) 1.20±0.03 0.94± 0.07* 0.86±0.08*
Left ventricular weight (g) 0.78±0.01 0.93± 0.09 0.85±0.08
Relative left ventricular weight (mg/g) 2.05±0.04 2.69± 0.26* 3.42±0.31*,†
Renin in clipped kidney (juxtaglomerular index, %) 22.4±1.5 30.5± 1.8* 31.2±3.0*
Serum creatinine (mg/dl) 0.20±0.01 0.22± 0.01 0.47±0.06*,†
Serum urea (mg/dl) 37.7±1.1 45.0± 2.9 122.3±18.3*,†
Plasma VEGF (pg/ml) 67.63±6.30 73.63± 7.83 105.82±15.67*
Plasma renin activity (ng Ang I/ml/h) 8.08±1.78 17.83± 3.20* 41.61±5.57*,†
Collagen I deposition in unclipped kidney (% area stained) 4.66±0.44 4.98± 1.02 10.16±1.53*,†
Tubulointerstitial PCNA-positive cells in unclipped kidney (no per cortical view) 4.43±2.23 10.71± 1.85* 11.79±1.60*
Glomerular PCNA-positive cells in unclipped kidney (no per glomerulus) 0.56±0.05 1.09± 0.13* 0.49±0.09†
PCNA-positive cells in left ventricle (number per view) 1.82±0.23 3.53± 0.62* 1.33±0.46†
Data are means ± sem. *p < 0.05 vs. sham,
†
p < 0.05 vs. non-malignant hypertension.
FIGURE 2 | Blood pressure measurements. (A) Intraarterial blood pressure
measurement in conscious animals at the end of the experiment. (B) Weekly
non-invasive blood pressure measurements using tail cuff plethysmography
under isoflurane anesthesia. Data are means ± sem. *p < 0.05 vs. sham OP
control. NMH, non-malignant hypertension; MH, malignant hypertension.
radioimmunoassay kit (Aldosterone Maia 12254, Serono
Diagnostics, Freiburg, Germany). Plasma renin activity was
measured with a commercially available radioimmunoassay kit
(DiaSorin, Stillwater, MN, USA). Plasma VEGF and soluble
VEGF receptor (Lip et al., 2000) were determined using
FIGURE 3 | Histology of the left ventricle. Photomicrographs
(representative for 24 control rats, 13 rats with non-malignant hypertension,
and 12 rats with malignant hypertension) of left ventricular sections stained
with α-smooth muscle actin in sham OP controls (A,D; sham), non-malignant
hypertension (B,E; NMH) and malignant hypertension (C,F; MH) with (C)
showing a vascular lesion and (F) showing a fibrotic myocardial area.
commercially available ELISA kits (both R&D Systems,
Wiesbaden, Germany) according to the manufacturer’s
protocol.
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FIGURE 4 | Disc angiogenesis assay. (A) Disc from a control animal (representative for n = 13). (B) Disc from an animal with non-malignant hypertension
(representative for n = 9). (C) Disc from an animal with malignant hypertension (representative for n = 9). (D) Evaluation of the disc angiogenesis assay. *p < 0.05 vs.
sham OP control, #p < 0.05 vs. non-malignant hypertension. (E) Exemplary photomicrograph of a PAS stained section of a disc from a control animal showing
immigrated cells stained in purple (granulation tissue). Asterisks mark disc matrix. (F) Photomicrograph of aRECA stained section of a disc showing endothelium of
blood vessels (arrows). Asterisks mark disc matrix.
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Tissue Sampling and Histological Analysis
After organ weighing, kidneys were decapsulated. Both poles
of each kidney and the apical tip of the left ventricle was
immediately snap frozen on liquid nitrogen for RNA extraction.
One 6mm slice of the kidney was snap frozen in TissueTek
for immunofluorescence stainings while another 6mm slice of
the remaining kidney and left ventricular tissue was put in
methyl-Carnoy solution (60% methanol, 30% chloroform, and
10% glacial acetic acid) for fixation. Paraffin embedded tissue was
sectioned and stained with periodic acid Schiff ’s (PAS) reagent.
Fibrinoid necroses and onion skin lesions were counted in PAS
stained renal sections by two different blinded observers in two
non-serial kidney sections in all contralateral kidneys exposed to
high blood pressure.
Immunohistochemistry
Tissue was processed as described (Menendez-Castro et al.,
2013). Immunohistochemical detection of renin (rabbit
antiserum kindly provided by Dr. Walter Fischli, Basel,
Switzerland), collagen I (2150-1908, Biogenesis, Poole, England),
α-smooth muscle actin 1A4 (Shantsila et al., 2010, DAKO,
Hamburg, Germany), rat endothelial cell antigen (RECA, HIS
52, AbD Serotec, Düsseldorf, Germany), CD31 (TLD-3A12,
BD Pharmingen, Heidelberg, Germany), and proliferating cell
nuclear antigen [PCNA, PC10 (Shantsila et al., 2010), DAKO,
Hamburg, Germany] was performed. All antibodies, except
for CD31, were used on paraffin-embedded tissue sections.
CD31 was used on cryosections. Interstitial collagen I was
quantified in 30 medium-power views (magnification x200)
by means of an 11 × 11 point grid. The percentage of grid
points corresponding with a stained area was calculated. As a
measure of kidney renin content the juxtaglomerular index was
calculated. In each kidney, 100–200 glomeruli were counted,
and the number of renin-positive glomeruli was expressed
as a percentage of the total number of glomeruli counted.
RECA or CD31 positive capillaries and PCNA positive cells
were counted in 5 (heart) or 20 (kidney) medium power
views (magnification x200 for RECA and PCNA on a Leitz
microscope and magnification x240 for CD31 on a Nikon
microscope). PCNA positive cells were also counted in 100
glomeruli per renal section. Proliferating endothelial cells
were counted after double staining for RECA and PCNA in 6
medium power views of paraffin embedded tissue. Myocardial
fibrosis was evaluated by looking for fibrotic areas (spanning
at least 10,000µm2 containing α-smooth muscle actin positive
myofibroblasts) in α-smooth muscle actin stained left ventricular
cross sections. Vascular damage in the left ventricle was evaluated
by counting vascular cross sections with excessive thickening
of the vascular wall and/or narrowing of the vascular lumen
after staining for α-smooth muscle actin in a complete cross
FIGURE 5 | Quantification of renal capillaries. (A–C) Photomicrographs of RECA stained renal sections (representative for 25 controls, 14 non-malignant
hypertensives, and 12 malignant hypertensive rats). (D) Evaluation of RECA stained capillary cross sections in paraffin-embedded renal tissue. (E–G)
Photomicrographs of immunofluorescent CD31 stained renal cryosections (representative for 9 controls, 6 non-malignant hypertensives, and 9 malignant hypertensive
rats). Evaluation of CD31 stained capillary cross sections in renal tissue. (H) Evaluation of CD31 stained capillary cross sections in frozen renal tissue. Please note that
the absolute number of capillaries per view is not directly comparable between panels (A–D) on the one hand, and panels (E–H) on the other hand, due to differences
in tissue fixation, sectioning, staining procedures, antibodies employed, detection methods (immunofluorescence vs. immunohistochemistry) and microscopes (see
Section Materials and Methods for details). Data are means ± sem. *p < 0.05 vs. sham OP control, #p < 0.05 vs. non-malignant hypertension. NMH, non-malignant
hypertension; MH, malignant hypertension.
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section of the left ventricle. To confirm the existence of blood
vessels in discs, frozen discs were cut and stained with a
RECA antibody detecting endothelial cells. All histological
evaluations were done by a single investigator blinded to the
group assignment.
Western Blot Analysis
Frozen renal tissue was homogenized, protein samples were
prepared as described (Menendez-Castro et al., 2014) and
separated on a denaturing SDS-PAGE gel (Laemmli, 1970).
After electrophoresis, the gels were electroblotted onto PVDF
membranes (Hybond-P, GE Amersham, Munich, Germany),
blocked with Rotiblock (Roth, Karlsruhe, Germany) for 1 h
and incubated overnight with a primary antibody to VEGF-A
(ab46154, Abcam, 1:1000). Protein bands were visualized with
secondary horseradish peroxidase-conjugated IgG antibodies
(Santa Cruz Biotechnology, 1:50000), using the ECL system (GE
Amersham, Freiburg, Germany). Blots were quantified using
a luminescent imager (LAS-1000, Fujifilm, Berlin, Germany)
and an Aida 2.1 image analysis software (Raytest, Berlin,
Germany). Loading of the blot was quantified by reprobing
with an antibody to tubulin (Sigma, Taufkirchen, Germany,
1:10000).
Real-Time Polymerase Chain Reaction
(PCR) Analyses
Myocardial and renal tissue was homogenized in RLT buffer
reagent (Qiagen, Hilden, Germany) with an ultraturrax for
30 s, total RNA was extracted from homogenates by RNeasy
Mini columns (Qiagen) according to the manufacturerer’s
protocol and real-time RT-PCR was performed (Gibson et al.,
1996). First-strand cDNA was synthesized with TaqMan
reverse transcription reagents (Applied Biosystems, Darmstadt,
Germany) using random hexamers as primers. Reactions
without Multiscribe reverse transcriptase were used as negative
controls for genomic DNA contamination. PCR was performed
with an ABI PRISM 7000 Sequence Detector System and
TaqMan or SYBR Green Universal PCR Master Mix (Applied
Biosystems), as described previously (Menendez-Castro et al.,
2014). All samples were run in triplicates. Specific mRNA levels
in hypertensive animals relative to sham operated controls
were calculated and normalized to a housekeeping gene
FIGURE 6 | Vascularisation of the left ventricle. (A–C) Photomicrographs of RECA stained heart sections (representative for 15 controls, 9 non-malignant
hypertensives, and 11 malignant hypertensive rats). (D) Evaluation of RECA stained capillary cross sections in heart tissue. Data are means ± sem. *p < 0.05 vs.
sham OP control, #p < 0.05 vs. non-malignant hypertension. NMH, non-malignant hypertension; MH, malignant hypertension.
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(18S) with the1-1-CT method as specified by the manufacturer
(http://www3.appliedbiosystems.com/cms/groups/mcb_support/
documents/generaldocuments/cms_040980.pdf). Primer pairs
used for experiments are shown in Table 1.
Statistical Analysis
One-way analysis of variance, followed by the Bonferroni post-
hoc test, was performed to test significance of differences between
groups. For repetitive measurements (time course of systolic
blood pressure), two-way analysis of variance was used. A p <
0.05 was considered significant. To assess the dis/agreement
between different observers or different methods to quantify
FIGURE 7 | Proliferation of endothelial cells (A), in the left ventricle and
(B), in renal tissue. Exemplary photomicrograph (C) showing double staining
for the endothelial cell marker RECA (black) and the proliferation marker PCNA
(brown, arrows) in renal tissue of a control animal. Data are means ± sem.
*p < 0.05 vs. sham OP control, #p < 0.05 vs. non-malignant hypertension.
EnC, endothelial cells; NMH, non-malignant hypertension; MH, malignant
hypertension.
FIGURE 8 | Measurements of plasma aldosterone levels and tissue
PAI-1 expression. (A) Serum aldosterone levels, (B), renal PAI-1 expression,
and (C), left ventricular PAI-1 expression. Data are means ± sem. *p < 0.05
vs. sham OP control, #p < 0.05 vs. non-malignant hypertension. NMH,
non-malignant hypertension; MH, malignant hypertension.
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continuous measurements, Spearman’s correlation coefficients
(Spearman’s rho) were calculated. Calculations were carried out
using the SPSS 19 software (IBM, Ehningen, Germany).
RESULTS
During 5 weeks of follow-up, 12 2K1C rats died or had to
be euthanized after severe weight loss and seizures and/or
hemiplegia. This substantial mortality is in line with the survival
of animals in similar rat models and reflects the severity of
the malignant form of the disease (Kantachuvesiri et al., 1999;
Biala et al., 2010). In the following paragraphs, results from 3
groups (sham operation= sham, non-malignant hypertension=
NMH and malignant hypertension = MH) are shown whereas
results for the 19 hypertensive 2K1C rats which were classified
as “undetermined” with regard to the presence of malignant
hypertension (see next paragraph) are presented in the online
supplement (Please see Table S1, Figures S2, S3)
Criteria for Malignant Hypertension
The occurrence of malignant hypertension was defined as the
presence of weight loss in these otherwise still growing rats
and characteristic vascular lesions in the contralateral kidney
(Figure 1) exposed to high blood pressure. Because malignant
hypertension may develop in 2K1C rats at different time points,
we suspected that some animals might present an intermediate
course. Therefore, we performed split-half analyses for both
criteria: weight loss and number of characteristic vascular lesions
(onion skin lesions and fibrinoid necroses). To avoid the need
for arbitrary definitions of “weight loss” (e.g., what percentage
of weight had to be lost? For how many days? How to deal
with several episodes of weight loss during observation?), the
actual weight gain between the 2K1C procedure and the end
of the study was used in the split-half analysis for “weight
loss.” In these growing rats, the animals with the most weight
loss had obviously the lowest weight gain during this time
(see Figure S4). Regarding the number of vascular lesions, the
correlation between both observers (Spearman’s rho) was 0.93.
Hypertension was considered malignant if a rat was in the upper
50% for both criteria (n = 13, MH), or non-malignant if animal
was lower 50% for both criteria (n = 15, NMH). Rats in the
upper 50% of one criterion but in the lower 50% for the other
were considered as “undetermined.”
End Organ Damage Is More Prominent in
Malignant Hypertension
For sham, MH and NMH groups, body weights were comparable
at the time of clipping of the renal artery (Table 2). Weight gain
over the 5 week observation period was somewhat reduced in
NMH compared to sham, but was most intensely reduced in MH
as compared to sham or NMH (Table 2 and data in Figure S3).
At the time of sacrifice the organ weights of the right unclipped
kidneys of MH and NMH were increased to the same degree
as compared to sham (Table 2). The left ventricular weights
increased with hypertension, however, they were higher in MH
compared to NMH (Table 2), despite comparable blood pressure
increases in NMH and MH (Figure 2). In accordance with the
results from the blood pressure measurements, the induction of
renin expression in the juxtaglomerular apparatus after clipping
of the left kidney was comparable in NMH and MH (Table 2).
On the other hand, plasma renin activity was more prominently
increased in MH compared to NMH (Table 2). Serum creatinine
levels and collagen I deposition in the right kidney as markers
of renal damage were both increased in MH only (Table 2).
While tubulointerstitial cell proliferation (PCNA positive cells)
was increased in both NMH and MH to a similar degree,
glomerular and left ventricular cell proliferation was increased
in NMH only (Table 2) (For representative photomicrographs
of renin, collagen I and PCNA stained renal sections see data
in Figure S5). Evaluation of vascular lesions in the left ventricle
revealed a significantly higher incidence of vascular lesions in
MH compared to NMH or sham (4.50± 0.72 vascular lesions per
ventricular cross section in MH vs. 1.38± 0.35 in NMH and 0.17
± 0.08 in sham, p < 0.05) as depicted in Figure 3. Fibrotic areas
in left ventricular tissue were only detected in MH (Figure 3F).
Neovascularization of Discs and
Capillarisation of Target Organs Is
Reduced in Malignant Hypertension
To evaluate neovascularization, a disc angiogenesis assay was
performed. There was a high agreement between both blinded
observers regarding the quantification of the area of vascular
ingrowth [correlation coefficient (Spearman’s rho): 0.929]. The
area of vascularisation was similar in sham and NMH, but
significantly reduced in MH (Figure 4). Vascularisation of the
right unclipped kidney was also reduced in MH compared
to sham and NMH, as assessed by two different markers
of capillaries (Figure 5). Similar results were obtained in
heart tissue, where the capillarisation of the left ventricular
myocardium was reduced in MH compared to sham and NMH
(Figure 6). In both left ventricular and renal tissue of NMH,
more proliferating endothelial cells were observed than in MH
(Figures 7A–C). Serum aldosterone levels were higher in both
NMH andMH compared to sham, but in MH serum aldosterone
levels were significantly higher than in NMH (Figure 8A). The
induction of renal and left ventricular plasminogen activator
inhibitor-1 (PAI-1) was more prominent in MH than in NMH
(Figures 8B,C).
Expression of VEGF and VEGF Receptors
Is Not Reduced in Malignant Hypertension
Plasma levels of VEGF were comparable between sham and
NMH, while significantly increased in MH (Table 2). Soluble
VEGF receptor 1 was not detectable in plasma in all but two
animals (only one MH and one NMH rat exhibited levels slightly
above detection limit, data not shown).
In the heart, the expression levels of VEGF A, B, C, D and
VEGF receptors 1, 2, 3 as well as the angiogenic factor placental
growth factor (PlGF) remained unchanged in NMH and MH,
with the exception of VEGF A expression which was significantly
reduced in MH compared to controls and VEGF D expression
which was significantly increased (Table 3). The expression of
the angiogenic factor angiopoietin-1 was reduced in NMH and
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TABLE 3 | Expression of angiogenic factors and receptors in the left ventricle [fold induction].
Left ventricle Sham-OP control Non-malignant hypertension Malignant hypertension
VEGF-A 1.00 ± 0.09 0.76± 0.08 0.56±0.06*
VEGF-B 1.00 ± 0.04 0.95± 0.11 0.72±0.09
VEGF-C 1.00 ± 0.07 1.27± 0.18 1.12±0.33
VEGF-D 1.00 ± 0.09 1.2± 0.10 1.95±0.44*
VEGF-receptor 1 1.00 ± 0.05 0.99± 0.16 0.95±0.14
VEGF-receptor 2 1.00 ± 0.09 1.06± 0.14 0.75±0.10
VEGF-receptor 3 1.00 ± 0.08 1.33± 0.16 1.67±0.60
PlGF 1.00 ± 0.04 1.42± 0.19 1.18±0.21
Angiopoietin-1 1.00 ± 0.10 0.48± 0.04* 0.39±0.07*
Angiopoietin-2 1.00 ± 0.10 1.31± 0.17 1.00±0.11
Tie1 1.00 ± 0.05 1.38± 0.17 0.88±0.13†
Tie2 1.00 ± 0.06 1.43± 0.16* 1.05±0.09
Data are means ± sem. *p < 0.05 vs. sham,
†
p < 0.05 vs. non-malignant hypertension.
TABLE 4 | Expression of angiogenic factors and receptors in the right (non-clipped) kidney [fold induction].
Right (non-clipped) kidney Sham-OP control Non-malignant hypertension Malignant hypertension
VEGF-A 1.00± 0.23 2.23±0.20* 2.72±0.26*
VEGF-B 1.00± 0.21 2.62±0.33* 3.87±0.24*,†
VEGF-C 1.00± 0.27 2.70±0.34* 4.94±0.40*,†
VEGF-D 1.00± 0.31 2.57±0.34 4.44±0.52*,†
VEGF-receptor 1 1.00± 0.21 2.31±0.31* 3.07±0.27*
VEGF-receptor 2 1.00± 0.23 2.33±0.31* 2.38±0.23*
VEGF-receptor 3 1.00± 0.29 2.92±0.47* 5.77±0.55*,†
PlGF 1.00± 0.19 2.73±0.35 4.13±0.24*,†
Angiopoietin-1 1.00± 0.87 1.59±0.18 1.82±0.14*
Angiopoietin-2 1.00± 0.23 1.84±0.21* 3.08±0.18*,†
Tie1 1.00± 0.25 1.43±0.15 1.54±0.10
Tie2 1.00± 0.25 1.62±0.18 1.78±0.13*
Data are means ± sem. *p < 0.05 vs. sham,
†
p < 0.05 vs. non-malignant hypertension.
MH to a similar degree, while the expression of angiopoietin-
2 remained unchanged. Expression analysis of the angiopoietin
receptors Tie1 and Tie2 revealed a slight reduction of Tie1 inMH
and a slight increase of Tie2 in NMH.
The expression of VEGF A, B, C, D, PIGF, VEGF receptors 1,
2, 3 and angiopoietin-2 was induced in the right kidneys of MH
and NMH (Table 4). The induction of renal VEGF B, C, D and
VEGF receptor 3 as well as PlGF and angiopoietin-2 expression
was significantly higher in MH than in NMH (Table 4). Western
blot evaluation of VEGF protein in the right kidneys did not yield
significant changes but showed the same trend as observed by
RT-PCR for gene expression of VEGF-A (Figure 9).
DISCUSSION
In our animal model of malignant hypertension organ damage
was associated with reduced capillarisation in the kidney and
the heart. Such an observation could be due to a reduced
formation of new capillaries, or to a loss of capillaries by
e.g., fibrotic processes. On the one hand, the reduced number
of proliferating cells in glomeruli and the left ventricle of
animals with malignant hypertension points to the former
mechanism. On the other hand, fibrotic processes in heart
and kidney especially in malignant hypertensives could lead
to a loss of capillaries. The reduced capillarisation could not
be attributed to an altered expression of several angiogenic
growth factors. To clarify this issue, we finally used a disc
angiogenesis model as a direct in vivo bioassay of the formation
of new vessels. Here, we observed reduced neovascularization
only in malignant hypertension but not in the non-malignant
course of the disease. However, we performed only an endpoint
measurement of these processes, not an investigation at
different time points, which is an important limitation of
our study.
The relationship between hypertension and angiogenic factors
and processes is often puzzling, and conflicting observations
have been reported. On the one hand, capillary rarefaction and
a reduced angiogenic potential was observed in some animal
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FIGURE 9 | Protein expression of VEGF-A in the right (non-clipped)
kidney as assessed by Western blot analysis. (A) Representative
photographs of Western blots. (B) Densitometric evaluation of VEGF protein in
relation to the housekeeper tubulin. Data are means ± sem. NMH,
non-malignant hypertension; MH, malignant hypertension.
models of hypertension (Belabbas et al., 2008; You et al.,
2008). Evidence for a reduced microvascular supply has been
described in humans with established essential hypertension
(Antonios et al., 1999a), with borderline essential hypertension
(Antonios et al., 1999b) and even in young adults with a
predisposition to hypertension (Noon et al., 1997). On the
other hand, in prehypertensive spontaneously hypertensive rats,
angiogenesis was found increased (Hudlett et al., 2005), and
increased levels of angiogenic growth factors were measured
in hypertensive patients with target organ damage (Nadar
et al., 2005). In rats with renovascular hypertension glomerular
VEGF A expression was induced (Advani et al., 2007). Plasma
VEGF levels were clearly induced in patients with essential
hypertension (Belgore et al., 2001). Ourmost striking observation
was the reduced neovascularization and capillarization in animals
with malignant hypertension, but not in animals with non-
malignant hypertension, despite the identical procedure to
induce hypertension, and the comparable blood pressure levels in
both groups. The results of our study indicate that the potential to
form and/or preserve new vessels is not uniform in hypertensive
disease and might be dependent on additional factors which also
determine the severity of hypertensive organ damage.
Our observations depend on the ability to distinguish between
malignant and non-malignant hypertension which was only
possible in retrospect from the animal’s course during follow-
up. Moreover, this distinction was rendered even more difficult
by the fact that we cannot be sure that a given animal would
not develop malignant hypertension later on if given the chance.
We therefore used rather strict definitions of malignant and
non-malignant hypertension, and excluded a substantial number
of animals with an intermediate course. The spontaneous
occurrence of the malignant hypertensive phenotype in some but
not all 2K1C rats has long been recognized (Möhring et al., 1976),
marked by weight loss, characteristic vascular lesions, and a more
marked stimulation of renin and aldosterone. The relatively small
(or even absent) difference of blood pressure between malignant
and non-malignant hypertension, despite markedly higher
plasma renin and aldosterone levels, is surprising but has been
noted previously (Möhring et al., 1976). In fact, some animals
experience a drop of blood pressure as malignant hypertension
occurs (Möhring et al., 1976). This observation may be due to
the loss of sodium and volume via the kidney (Möhring et al.,
1976). In this situation, stimulation of the renin-angiotensin-
aldosterone system may be crucial to maintain high blood
pressure, which could explain the exquisite sensitivity to very
low doses of inhibitors of the renin-angiotensin system (Hilgers
et al., 2001). In accordance with this observation, we previously
reported that the occurrence of malignant hypertension in the
2K1C rat model can be prevented by low-dose angiotensin II type
1 receptor blockade (Hilgers et al., 2001). A similar phenomenon
has been described in another renin-driven transgenic model
(Whitworth et al., 1995) of hypertension.
In some regards, malignant and non-malignant may appear
as merely ends of a spectrum, but there was a rather clear-
cut difference regarding capillary supply and neovascularization:
There was simply no impairment in non-malignant hypertension
but a marked decrease in malignant hypertensive rats. In fact,
there was even a trend toward increased capillary supply in the
contralateral kidney of non-malignant hypertensive rats which
might be explained by some degree of compensatory hypertrophy
(Schwartz et al., 1993). Previous findings of increased VEGF in
hypertension (Belgore et al., 2001; Advani et al., 2007) are in
line with our own observations of an increase in renal VEGF A
expression in both malignant and non-malignant hypertension.
Moreover, we detected an induction of several VEGF isoforms
and receptors in the kidneys of hypertensive rats. In contrast
to the impaired capillary supply, the expression of VEGFs and
VEGF receptors were not reduced in malignant hypertension,
with the exception of myocardial VEGF A. Some renal VEGF
isoforms and plasma VEGF levels were even higher in malignant
hypertension than in non-malignant hypertension and controls.
Thus, capillary rarefaction in malignant hypertension cannot
be explained as a consequence of reduced expression of these
angiogenic factors. Rather, overexpression of VEGF as seen
in various hypertensive models (Advani et al., 2007; Belabbas
et al., 2008) might serve a protective function. However,
overexpression of VEGF isoforms and VEGF receptors as seen
in our animal model neither protected against the development
of malignant hypertension nor against capillary rarefaction. The
increased expression of angiopoietin-2 in the right kidney of
malignant hypertension might be interesting and worthy of
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further study in view of previous reports on the association of
circulating angiopoietin-2 with renal injury in chronic kidney
disease (Chang et al., 2013; Tsai et al., 2014). However, this
pattern of expression was limited to the right kidney, and was
not present in the left ventricle. Such an observation thus appears
unlikely to explain the capillary rarefaction which was seen in
both organs.
Malignant hypertensive rats exhibited a more pronounced
stimulation of plasma renin and aldosterone, as described
previously (Möhring et al., 1976). In other models of
hypertension, high aldosterone leads to an overexpression
of PAI-1 (Brown et al., 2000; Ma et al., 2006). The effects of
PAI-1 on vessel formation are quite complex (Stefansson et al.,
2003), but the protein can certainly inhibit angiogenesis in vivo
(Stefansson et al., 2001). We demonstrated that malignant
hypertension, impaired disc neovascularization and reduced
capillary supply of target organs are associated with elevated
expression of PAI-1 in the heart and the contralateral kidney but
our study is limited in that we cannot establish a cause-and-effect
relationship. Further, we cannot exclude the possibility, that the
more severe renal injury in malignant hypertension could in turn
cause an impairment of angiogenic processes. Such an impaired
post-ischemic angiogenesis has been described previously in
a normotensive rat model of more severely impaired kidney
function (5/6 nephrectomy) of longer duration (Jacobi et al.,
2006).
While we are at present unable to clearly delineate a
mechanism, our data show that only malignant hypertension, not
non-malignant hypertension, is characterized by a reduced disc
neovascularization and by a reduced capillarisation of the kidney
and heart. This observation may lead to a better understanding
of the puzzling relationship between vasculogenic processes,
hypertension and target organ damage. Moreover, therapeutic
interventions to induce a coordinated program stimulating
angiogenesis (for example via Hypoxia-Inducing Factors) may
hold promise to prevent progressive target organ damage in
malignant hypertension.
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